B. Ljungberg, S. Campbell, H. Choi, D. Jacqmin, J. Lee et al., The Epidemiology of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.615-636, 2011.
DOI : 10.1016/j.eururo.2011.06.049

M. Murai and M. Oya, Renal cell carcinoma: etiology, incidence and epidemiology, Current Opinion in Urology, vol.14, issue.4, pp.229-262, 2004.
DOI : 10.1097/01.mou.0000135078.04721.f5

L. Gossage, T. Eisen, and E. Maher, VHL, the story of a tumour suppressor gene, Nature Reviews Cancer, vol.62, issue.1, pp.55-64, 2015.
DOI : 10.1038/sj.onc.1206373

S. Abdullah and R. Perez-soler, Mechanisms of resistance to vascular endothelial growth factor blockade, Cancer, vol.13, issue.pt 1, pp.3455-67, 2012.
DOI : 10.1158/1078-0432.CCR-07-1393

L. Harshman and T. Choueiri, Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma, The Cancer Journal, vol.19, issue.4, pp.316-339, 2013.
DOI : 10.1097/PPO.0b013e31829e3c9a

C. Zhu, J. Xu, M. Li, G. Zhao, and H. Cao, Heterogeneity of c-Met expression in Chinese gastric cancer 321 patients, Human pathology, vol.46, issue.12, 2015.

L. Albiges, J. Guegan, L. Formal, A. Verkarre, V. Rioux-leclercq et al., MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array, Clinical Cancer Research, vol.20, issue.13, pp.3411-3432, 2014.
DOI : 10.1158/1078-0432.CCR-13-2173
URL : https://hal.archives-ouvertes.fr/hal-01064619

J. Patard, N. Rioux-leclercq, D. Masson, S. Zerrouki, F. Jouan et al., Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma, British Journal of Cancer, vol.94, issue.8, pp.1417-1441, 2009.
DOI : 10.1093/jnci/94.20.1569
URL : https://hal.archives-ouvertes.fr/inserm-00418630

J. Patard, P. Fergelot, P. Karakiewicz, T. Klatte, Q. Trinh et al., Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma, International Journal of Cancer, vol.98, issue.2, pp.395-400, 2008.
DOI : 10.1111/j.1464-410X.2006.06376.x
URL : https://hal.archives-ouvertes.fr/hal-00278587

S. Kammerer-jacquet, L. Crouzet, A. Brunot, J. Dagher, A. Pladys et al., Independent 336 association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with 337 therapeutic potential, International journal of cancer Journal international du cancer

S. Shin, Y. Jeon, P. Kim, Y. Cho, J. Koh et al., Clinicopathologic Analysis of PD-L1 and 340 PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status, Ann Surg, p.341

N. Rioux-leclercq, P. Karakiewicz, Q. Trinh, V. Ficarra, L. Cindolo et al., Prognostic ability of simplified nuclear grading of renal cell carcinoma, Cancer, vol.127, issue.5, pp.868-74, 2007.
DOI : 10.1002/cncr.22463

M. Bui, D. Seligson, K. Han, A. Pantuck, F. Dorey et al., Carbonic anhydrase IX is an 345 independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis 346 and therapy, Clin Cancer Res, vol.9, issue.2, pp.802-813, 2003.

M. Belaud-rotureau, M. Parrens, N. Carrere, M. Turmo, J. Ferrer et al., Interphase 351 fluorescence in situ hybridization is more sensitive than BIOMED-2 polymerase chain reaction 352 protocol in detecting IGH-BCL2 rearrangement in both fixed and frozen lymph node with follicular 353 lymphoma. Human pathology, pp.365-72, 2007.

P. Jurmeister, D. Lenze, E. Berg, S. Mende, F. Schaper et al., Parallel screening for ALK, MET 355 and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing, Lung, vol.356

J. Jeuken, S. Cornelissen, M. Vriezen, M. Dekkers, A. Errami et al., MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas, Laboratory Investigation, vol.349, issue.10, pp.1055-65, 2007.
DOI : 10.1038/labinvest.3700664

S. Macher-goeppinger, M. Keith, V. Endris, R. Penzel, K. Tagscherer et al., MET 361 expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential 362 predictive marker, Oncotarget, vol.8, issue.1, pp.1046-57, 2017.

K. Wethmar, J. Schulz, E. Muro, S. Talyan, M. Andrade-navarro et al., Comprehensive 364 translational control of tyrosine kinase expression by upstream open reading frames, Oncogene, vol.36535, issue.13, pp.1736-1778, 2016.

G. Gibney, S. Aziz, R. Camp, P. Conrad, B. Schwartz et al., c-Met is a prognostic marker 367 and potential therapeutic target in clear cell renal cell carcinoma Annals of oncology : official journal 368 of the European Society for Medical Oncology, ESMO, vol.24, issue.2, pp.343-352, 2013.

G. Banumathy and P. Cairns, Signaling pathways in renal cell carcinoma, Cancer Biology & Therapy, vol.7, issue.7, pp.658-64, 2010.
DOI : 10.1200/JCO.2008.20.0766

L. Worley, Cabozantinib and nivolumab for renal cell carcinoma, The Lancet Oncology, vol.16, issue.15, 2015.
DOI : 10.1016/S1470-2045(15)00377-0

F. Shojaei, J. Lee, B. Simmons, A. Wong, C. Esparza et al., HGF/c-Met acts as an 382 alternative angiogenic pathway in sunitinib-resistant tumors. Cancer research, 2010.

L. Zhou, X. Liu, M. Sun, X. Zhang, P. German et al., Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma, Oncogene, vol.147, issue.21, pp.2687-97, 2016.
DOI : 10.1200/JCO.2008.21.3660

B. Keith, R. Johnson, and M. Simon, HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour 388 growth and progression, Nat Rev Cancer, vol.12, issue.1, pp.9-22, 2012.

V. Robb, M. Karbowniczek, A. Klein-szanto, and E. Henske, Activation of the mTOR signaling pathway 393 in renal clear cell carcinoma. The Journal of urology, pp.346-52, 2007.

M. Mendoza, E. Er, and J. Blenis, The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation, Trends in Biochemical Sciences, vol.36, issue.6, pp.320-328, 2011.
DOI : 10.1016/j.tibs.2011.03.006

B. Os, median survival: low: 22 months, p.20